PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2084802
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2084802
Brain Cancer Therapeutics Market is estimated to be valued at USD 4,052 Mn in 2026 and is expected to reach USD 7,796.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4,052 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.80% | 2033 Value Projection: | USD 7,796.3 Mn |
Cancer is one of the most prevalent and fatal chronic disorders with a high mortality rate. Throughout our lives, healthy cells in our bodies divide and replace themselves in a controlled fashion. Cancer starts when a cell is altered and it multiplies out of control. A tumor is formed when such abnormal cells grow to form a mass. Cancer cells grow to form tumor that interfere with brain functions such as muscle control, memory, sensation, and other normal bodily functions. Symptoms of brain cancer vary but often include weakness, difficulty walking, dizziness, seizures, and headaches.
The brain and spinal column make up the central nervous system (CNS), where all important functions are controlled. These functions include thought, body movements, and speech. This means that when a tumor grows in the CNS, it can affect a person's thought processes or the way they move or talk. A treatment plan is individualized and planned for each brain cancer patient depending on certain factors. The treatment plan is constructed by the doctors who are specialized in brain cancer, and treatments vary widely depending on the type of cancer, brain location of the tumor, tumor size, patient age, and the general health status of the patient. A major part of the plan is also determined by the wish of the patient.
The increasing launches of new drugs and regulatory approvals for brain cancer therapeutics are expected to drive the market growth during the forecast period. For instance, in June 2020, Food and Drug Administration (FDA) has granted fast track designation to TVAX Biomedical, Inc. for TVI-Brain-1, an adoptive T cell therapy for the treatment of glioblastoma multiforme. TVI-Brain-1 (TVAX Biomedical) is an autologous, vaccine-enhanced adoptive T-cell therapy consisting a proprietary vaccine pretreatment to create cancer-specific T cells and an activated antitumor T-cell treatment. The Fast Track Designation was supported by positive Phase 2 clinical data in addition to extensive preclinical and Phase 1 safety studies.